# A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

> **NCT07677059** · PHASE2 · RECRUITING · sponsor: **Kymera Therapeutics, Inc.** · enrollment: 264 (estimated)

## Conditions studied

- Asthma (Diagnosis)

## Interventions

- **DRUG:** KT-621

## Key facts

- **NCT ID:** NCT07677059
- **Lead sponsor:** Kymera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-25
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2026-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677059, "A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07677059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*